Article
Cardiac & Cardiovascular Systems
Meaghan E. Colling, Benjamin E. Tourdot, Yogendra Kanthi
Summary: The association between inflammation, infection, and venous thrombosis is crucial and can lead to pathological thrombosis. Cells like neutrophils, monocytes, and platelets play essential roles in host defense and thrombus formation. Understanding these mechanisms has advanced knowledge in human physiology and pathophysiology, offering new therapeutic targets for the treatment of thrombosis.
CIRCULATION RESEARCH
(2021)
Article
Hematology
Frits I. Mulder, Noemie Kraaijpoel, Marc Carrier, Noori A. Guman, Luis Jara-Palomares, Marcello Di Nisio, Walter Ageno, Jan Beyer-Westendorf, Frederikus A. Klok, Thomas Vanassche, Hans-Martin B. Otten, Benilde Cosmi, Marije ten Wolde, Sjors G. J. G. In 't Veld, Edward Post, Jip Ramaker, Kenn Zwaan, Mike Peters, Aurelien Delluc, Pieter W. Kamphuisen, Veronica Sanchez-Lopez, Ettore Porreca, Patrick M. M. Bossuyt, Harry R. Buller, Thomas Wurdinger, Myron G. Best, Nick van Es
Summary: Platelet RNA sequencing showed poor diagnostic accuracy for detecting occult cancer in patients with unprovoked venous thromboembolism.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Oncology
Helene Helfer, Yara Skaff, Florent Happe, Sadji Djennaoui, Jean Chidiac, Geraldine Poenou, Marc Righini, Isabelle Mahe
Summary: The current recommended VTE diagnostic approach is less satisfactory in cancer patients due to their nonspecific VTE symptoms and increased D-dimer levels associated with the tumor process. Several approaches have been developed to improve VTE exclusion in cancer patients, but there is still a lack of a dedicated diagnostic algorithm for this population.
Article
Hematology
Monique J. T. Crobach, Rayna J. S. Anijs, Sigrid K. Braekkan, Marianne T. Severinsen, Jens Hammerstrom, Hanne Skille, Soren R. Kristensen, Benedikte Paulsen, Anne Tjonneland, Henri H. Versteeg, Kim Overvad, John-Bjarne Hansen, Inger A. Naess, Suzanne C. Cannegieter
Summary: Patients with cancer have a higher risk of developing venous thromboembolism (VTE), which leads to poorer survival compared to cancer alone. This study aimed to investigate the impact of VTE on cancer patients' survival in a general population. The findings showed that cancer patients with VTE had a 3.4-fold higher risk of death compared to those without VTE, regardless of cancer type.
Article
Hematology
Michela Giustozzi, Jean M. Connors, Ana Belen Ruperez Blanco, Sebastian Szmit, Nicolas Falvo, Alexander T. Cohen, Menno Huisman, Rupert Bauersachs, Francesco Dentali, Cecilia Becattini, Giancarlo Agnelli
Summary: Cancer patients with incidental and symptomatic VTE have different clinical features and outcomes, with incidental VTE patients having a lower incidence of recurrent VTE and a higher incidence of major bleeding. The relative efficacy and safety of apixaban and dalteparin were similar for both types of VTE.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Oncology
Takaki Yoshikawa, Takeshi Sano, Masanori Terashima, Kensei Yamaguchi, Etsuro Bando, Ryohei Kawabata, Hiroshi Yabusaki, Hisashi Shinohara, Mari S. Oba, Tetsuya Kimura, Atsushi Takita, Mitsuru Sasako
Summary: This study is a large-scale, multicenter, prospective registry that aims to investigate the incidence and risk factors of venous thromboembolism (VTE) in adult Japanese patients with solid tumors. The analysis of stomach cancer patients revealed that female sex, age >= 65 years, VTE history, and D-dimer > 1.2 μg/mL were independent risk factors for VTE. Additionally, screening for D-dimer before starting cancer treatment is necessary, even for asymptomatic patients.
Review
Oncology
Salah Eddine Ousama Kacimi, Aysan Moeinafshar, Shirin Shahsavar Haghighi, Amene Saghazadeh, Nima Rezaei
Summary: VTE is a clinical disease that frequently occurs in cancer patients, and immunotherapy, although effective for cancer treatment, can also increase the risk of VTE.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Hematology
David Spirk, Tim Sebastian, Stefano Barco, Martin Banyai, Juerg H. Beer, Lucia Mazzolai, Thomas Baldi, Drahomir Aujesky, Daniel Hayoz, Rolf P. Engelberger, Thomas Kaeslin, Wolfgang Korte, Robert Escher, Marc Husmann, Marc Blondon, Nils Kucher
Summary: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. After comparing baseline characteristics, anticoagulation therapy, all-cause mortality, and VTE recurrence rates at 90 days between patients with incidental and symptomatic VTE, the study found that receiving anticoagulation therapy for at least 3 months was associated with lower mortality and recurrence rates in patients with incidental VTE regardless of cancer status. Additionally, among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Oncology
Deanna Glassman, Nicholas W. Bateman, Sanghoon Lee, Li Zhao, Jun Yao, Yukun Tan, Cristina Ivan, Kelly M. Rangel, Jianhua Zhang, Kelly A. Conrads, Brian L. Hood, Tamara Abulez, P. Andrew Futreal, Nicole D. Fleming, Vahid Afshar-Kharghan, George L. Maxwell, Thomas P. Conrads, Ken Chen, Anil K. Sood
Summary: Ovarian cancer patients with venous thromboembolism (VTE) have molecular differences compared to those without. VTE is associated with upregulated inflammatory and coagulation pathways, and correlated with the expression of platelet-derived growth factor subunit B (PDGFB) and extracellular proteins, namely collagens.
Article
Hematology
Alexander Cohen, Virginia Noxon, Amol Dhamane, Robert Bruette, Shrushti Shah, Dionne M. Hines, Tamuno Alfred, Xuemei Luo
Summary: This study compared the risks of recurrent venous thromboembolism (VTE), major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among cancer patients with brain cancer and other types of cancer who initiated apixaban, low molecular weight heparin (LMWH), or warfarin. The results showed that apixaban was associated with a lower risk of these adverse events compared to LMWH and warfarin, and there were no significant differences in the anticoagulant treatment effects between patients with brain cancer and those with other cancer.
THROMBOSIS RESEARCH
(2023)
Article
Oncology
Hirotsugu Kenmotsu, Akifumi Notsu, Keita Mori, Shota Omori, Takahiro Tsushima, Yasuomi Satake, Yoshihiro Miki, Masakazu Abe, Masahito Ogiku, Toshio Nakamura, Masakazu Takagi, Hideto Ochiai, Hirofumi Yasui, Toshiaki Takahashi
Summary: This study revealed a high incidence of VTE in patients with advanced cancer, particularly in those with lung cancer. Although most VTE cases were asymptomatic, intensive screening may be necessary, especially for female patients with elevated D-dimer levels and decreased platelet counts.
Review
Biochemistry & Molecular Biology
Mario Enrico Canonico, Ciro Santoro, Marisa Avvedimento, Giuseppe Giugliano, Giulia Elena Mandoli, Maria Prastaro, Anna Franzone, Raffaele Piccolo, Federica Ilardi, Matteo Cameli, Giovanni Esposito
Summary: Acute thrombotic events can reveal occult cancer in a significant number of cases. Malignancy interacts with the hemostatic system, leading to both thrombosis and bleeding. Cancer-related thrombotic events primarily affect the venous side and present in various conditions, including unusual sites of venous thrombosis. The selection of patients for anticoagulation management is complex, taking into account individual patient goals and preferences, prognosis of specific cancers, comorbidities, drug interactions, underweight states, and competing risks of morbidity and mortality. Anticoagulant treatment in cancer is widely debated, with direct oral anticoagulants showing efficacy and safety compared to traditional treatment.
Article
Education, Scientific Disciplines
Bo Liang, Yi Liang, Li-Zhi Zhao, Yu-Xiu Zhao, Ning Gu
Summary: Rivaroxaban is effective in reducing recurrent VTE and shows good safety outcomes in cancer patients. Further randomized controlled trials are needed to confirm these results.
Review
Hematology
Rayna J. S. Anijs, Yen Nhi Nguyen, Suzanne C. Cannegieter, Henri H. Versteeg, Jeroen T. Buijs
Summary: MicroRNAs (miRNAs) are small noncoding RNAs with gene regulatory functions that can serve as promising biomarkers for the diagnosis and prediction of cancer and cardiovascular diseases. They play important roles in regulating the pathophysiology of venous thromboembolism (VTE) and cancer-associated thrombosis (CAT). Validation studies using comparable patient populations are needed to determine the potential use of miRNAs as standalone or incorporated biomarkers in risk prediction models for VTE and CAT.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Oncology
Derman Basaran, Thomas Boerner, Jessa Suhner, Dib Sassine, Ying Liu, Rachel N. Grisham, William P. Tew, Ginger J. Gardner, Oliver Zivanovic, Yukio Sonoda, Kara Long Roche, Dennis S. Chi, Nadeem R. Abu-Rustum, Gerald A. Soff, Elizabeth L. Jewell
Summary: The study aimed to determine the incidence of VTE in patients receiving neoadjuvant chemotherapy for ovarian cancer, finding that FIGO stage IV disease was the only factor associated with increased risk for new-onset VTE.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Hematology
Cihan Ay, Katarina D. Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C. Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger
Summary: This study evaluated the safety, pharmacokinetics, and pharmacodynamics of rondaptivon pegol in patients with hemophilia A. The results showed that rondaptivon pegol was well tolerated and significantly increased the levels of FVIII and VWF in patients with hemophilia A.
Review
Hematology
Robert Klamroth, Cihan Ay, Philippe De Moerloose, Pierre Fontana, Jerzy Windyga, Jan Astermark, Erik Berntorp, Manuela Carvalho, Gerard Dolan, Cedric Hermans, Pal Andre Holme, Gili Kenet, Maria Elisa Mancuso, Natascha Marquardt, Ramiro Nunez, Ingrid Pabinger, Ryan Rodgers, Paul van der Valk, Victor Jimenez Yuste, Irena Preloznik Zupan
Summary: As people with haemophilia receive better treatment and live longer, they are more likely to develop cardiovascular disease and other comorbidities. This study reviewed the guidelines for the acute management of patients with acute coronary syndrome and proposed relevant adaptations for haemophilia A patients without inhibitors who are on prophylaxis and present with ACS.
Article
Hematology
Nicola Potere, Stefano Barco, Isabelle Mahe, Gabriela Cesarman-Maus, Pantep Angchaisuksiri, Avi Leader, Helen C. Okoye, Edeghonghon Olayemi, Cihan Ay, Marc Carrier, Jean Marie Connors, Ioannis T. Farmakis, Riccardo M. Fumagalli, Zhi-Cheng Jing, Lai Heng Lee, Claire McLintock, Fionnuala Ni Ainle, George Giannakoulas, Shinya Goto, Maria Cecilia Guillermo Esposito, Luis Jara-Palomares, Marta Szlaszynska, Chee Wee Tan, Nick Van Es, Tzu-Fei Wang, Beverley J. Hunt, Marcello Di Nisio
Summary: The preliminary results of a patient-centered survey on cancer-associated venous thromboembolism (CAT) show significant knowledge gaps among cancer patients, with many lacking awareness of their CAT risk and information on VTE signs and symptoms and anticoagulant-related risks.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Hematology
Florian Moik, Cihan Ay
Summary: Patients with cancer often have dysregulation of the hemostatic system and systemic hypercoagulability. Hemostatic biomarkers can be utilized to predict cancer activity and clinical outcomes.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Biochemistry & Molecular Biology
Cornelia Englisch, Oliver Koenigsbruegge, Stephan Nopp, Florian Moik, Peter Quehenberger, Matthias Preusser, Ingrid Pabinger, Cihan Ay
Summary: Venous and arterial thromboembolism are common complications in cancer patients. The connection between antithrombin deficiency and cancer-associated thrombosis is unclear. This study investigated the association of antithrombin activity levels with the risk of cancer-associated thrombosis and all-cause mortality in cancer patients. Antithrombin showed a U-shaped association with the risk of all-cause death, with both low and high levels associated with poorer overall survival. In patients with brain tumors, higher antithrombin levels were associated with the risk of thrombosis and mortality. However, no association was found between antithrombin and cancer-associated thrombosis in all cancer types, except for brain tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Transplantation
Stephan Nopp, Oliver Koenigsbruegge, Sabine Schmaldienst, Renate Klauser-Braun, Matthias Lorenz, Ingrid Pabinger, Marcus Saeemann, Cihan Ay
Summary: This study found that in patients with end-stage kidney disease (ESKD), growth differentiation factor-15 (GDF-15) can predict the risk of major bleeding, cardiovascular events, and death, and may be a valuable marker for guiding treatment decisions.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Medicine, General & Internal
Loris Wauthier, Julien Favresse, Michael Hardy, Jonathan Douxfils, Gregoire Le Gal, Pierre-Marie Roy, Nick van Es, Cihan Ay, Hugo ten Cate, Thierry Vander Borght, Michael V. Dupont, Thomas Lecompte, Giuseppe Lippi, Francois Mullier
Summary: D-dimer is a multifaceted biomarker used for ruling out pulmonary embolism and/or deep vein thrombosis. The accuracy of the test depends on the assay used and may be affected by diagnostic errors occurring throughout the testing phases.
Article
Health Care Sciences & Services
Rayyan Hemetsberger, Serdar Farhan, Dominika Lukovic, Katrin Zlabinger, Judit Hajagos-Toth, Judit Bota, Hector M. Garcia-Garcia, Cihan Ay, Eslam Samaha, Robert Gaspar, Rita Garamvoelgyi, Kurt Huber, Andreas Spannbauer, Mariann Gyoengyoesi
Summary: Peri-interventional triple therapy with dabigatran in a pig model of coronary artery stenting has been found to ameliorate local inflammation and disturb vasomotion, without reducing neointimal formation.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Stephan Nopp, M. Leontien van der Bent, Daniel Kraemmer, Oliver Koenigsbruegge, Johann Wojta, Ingrid Pabinger, Cihan Ay, Anne Yael Nossent
Summary: In this study, the researchers investigated the potential of circulating microRNAs as prognostic biomarkers for major adverse cardiovascular events in patients with atrial fibrillation. The results suggest that miR-411-5p could be a valuable biomarker for predicting MACE in AF patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Stephan Nopp, Julia Bohnert, Thomas Mayr, Daniel Steiner, Helmut Prosch, Irene Lang, Wilhelm Behringer, Karin Janata-Schwatczek, Cihan Ay
Summary: This study describes the characteristics, discharge, and outcome of outpatients diagnosed with acute pulmonary embolism (PE) at a tertiary care center. Results showed that 156 out of 709 patients (22%) were discharged and received home treatment, with a 2.4-fold increase in home treatment rates during the study period. The 30-day mortality rate was 4.9%.
INTERNAL AND EMERGENCY MEDICINE
(2023)
Article
Oncology
Johannes Thaler, Gerald Prager, Ingrid Pabinger, Cihan Ay
Summary: Using a modified plasma clot formation assay, we found an increased plasma clot formation rate and fibrin fiber thickness in pancreatic cancer patients compared to healthy controls. When a tissue factor blocking antibody was added, the clot formation rate decreased significantly in patients, fibrin fiber thickness decreased in patients and controls, the lag phase remained unchanged, and the time to peak fibrin generation increased in patients. These findings suggest the presence of a prothrombotic state in pancreatic cancer patients, dependent on tissue factor.
Review
Hematology
Cihan Ay, Laurent Frenzel, Karen Pinachyan, Sandra Le Quellec
Summary: This article aims to provide a comprehensive summary of the whole process of AAV-based gene therapy, from basic principles to clinical implementation, through an illustrated review.
Article
Hematology
Stephan Nopp, Florian Moik, Simon Kraler, Cornelia Englisch, Matthias Preusser, Arnold von Eckardstein, Ingrid Pabinger, Thomas F. Luescher, Cihan Ay
Summary: GDF-15 is strongly associated with survival in cancer patients, independent of established risk factors. Although an association was identified with ATE and VTE in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Meaghan E. Colling, Cihan Ay, Daniel Kraemmer, Silvia Koder, Peter Quehenberger, Ingrid Pabinger, Florian Posch, Johanna Gebhart
Summary: Data on the stability of lupus anticoagulant (LA) test results and their implications on clinical outcomes are limited for persistently positive LA patients. This study followed 164 patients and found a 28% incidence of negative LA tests during the observation period. However, a negative LA test did not predict future thrombotic events or mortality in these patients.
Article
Hematology
Helmut Schweiger, Judit Rejto, Christoph J. Hofbauer, Verena Berg, Peter Allacher, Karl Zwiauer, Clemens Feistritzer, Gerhard Schuster, Cihan Ay, Birgit M. Reipert, Ingrid Pabinger
Summary: This study analyzed nonneutralizing FVIII-specific antibody responses in hemophilia A patients and healthy individuals and found that IgG1 and IgA were the dominant antibodies. The prevalence, titers, and affinities of these nonneutralizing antibodies were higher in hemophilia A patients compared to healthy subjects. The presence of elevated titers of FVIII-specific IgA was observed in sHA patients with active or past HCV infection. Increased titers and affinities of FVIII-specific IgG1 antibodies were also found in a considerable number of hemophilia A patients.
